[Treatment of gonorrheal urethritis in men using kanamycin and vibramycin].
The therapeutic efficiency of kanamycin and vibromycin in treatment of gonorrhea was studied on 112 and 86 males respectively. Clinical and etiological recovery was observed in 85.6 and 92.9 per cent of the patients. The best therapeutic results were obtained with the use of vibromycin in a course dose of 500 mg. A single administration of the drug in a course dose of 300 mg was less effective. The gonococci disappeared from the urethra secretion under the effects of kanamycin and vibromycin 4-10 hours after beginning of the treatment. The minimum concentration of vibromycin inhibiting the gonococcal growth on nutrient media ranged from 0.02 to 0.4 units/ml.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002908:Chronic Disease; D004318:Doxycycline / Q000627:therapeutic use*; D006069:Gonorrhea / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007612:Kanamycin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009344:Neisseria gonorrhoeae / Q000187:drug effects; D010406:Penicillins / Q000494:pharmacology; D014481:United States; D014526:Urethritis / Q000188:drug therapy* / Q000382:microbiology
D000900:Anti-Bacterial Agents; D010406:Penicillins; D007612:Kanamycin; D004318:Doxycycline
Lechenie gonoreĭnykh uretritov u muzhchin kanamitsinom i vibramitsinom